About Hemispherx BioPharma (NYSE:HEB)
Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NYSE:HEB
- CUSIP: N/A
- Web: www.hemispherx.net/
- Market Cap: $9.48 million
- Outstanding Shares: 29,169,000
- 50 Day Moving Avg: $0.33
- 200 Day Moving Avg: $0.47
- 52 Week Range: $0.30 - $1.15
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -10.83
- P/E Growth: 0.000
- Annual Revenue: $335,000.00
- Price / Sales: 28.30
- Book Value: $0.36 per share
- Price / Book: 0.91
- EBITDA: ($12,100,000.00)
- Net Margins: -1,029.58%
- Return on Equity: -75.57%
- Return on Assets: -53.36%
- Average Volume: 256,511 shs.
- Short Ratio: 1.42
Frequently Asked Questions for Hemispherx BioPharma (NYSE:HEB)
What is Hemispherx BioPharma's stock symbol?
Hemispherx BioPharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "HEB."
How were Hemispherx BioPharma's earnings last quarter?
Hemispherx BioPharma, Inc (NYSE:HEB) announced its earnings results on Monday, August, 14th. The company reported ($0.08) EPS for the quarter. The firm had revenue of $0.21 million for the quarter. Hemispherx BioPharma had a negative return on equity of 75.57% and a negative net margin of 1,029.58%. View Hemispherx BioPharma's Earnings History.
Are investors shorting Hemispherx BioPharma?
Hemispherx BioPharma saw a increase in short interest in September. As of September 29th, there was short interest totalling 1,100,251 shares, an increase of 17.2% from the September 15th total of 938,792 shares. Based on an average trading volume of 263,493 shares, the short-interest ratio is presently 4.2 days. Currently, 4.0% of the shares of the stock are short sold.
Who are some of Hemispherx BioPharma's key competitors?
Some companies that are related to Hemispherx BioPharma include Cerulean Pharma (DARE), Ritter Pharmaceuticals (RTTR), Anthera Pharmaceuticals (ANTH), Evgen Pharma PLC (EVG), Opexa Therapeutics (ACER), Proteome Sciences plc (PRM), Kitov Pharmaceuticals Holdings (KTOV), Bio Blast Pharma (ORPN), ValiRx Plc (VAL), Ariad Pharmaceuticals (ARIA), Auspex Pharmaceuticals (ASPX), Biotie Therapies Corp (BITI), Cynapsus Therapeutics (CYNA), Dyax Corp. (DYAX), Kythera Biopharmaceuticals (KYTH), Medivation (MDVN), MEI Pharma (MSHL) and Nexvet Biopharma plc (NVET).
Who are Hemispherx BioPharma's key executives?
Hemispherx BioPharma's management team includes the folowing people:
- William M. Mitchell, Chairman of the Board
- Thomas K. Equels Esq., Executive Vice Chairman, Chief Executive Officer, President, Secretary, & General Counsel
- Adam Pascale CPA, Chief Financial Officer
- Wayne Steven Springate, Senior Vice President - Operations
- David R. Strayer M.D., Chief Scientific & Medical Officer
- Peter W. Rodino III, Esq., Executive Director - Governmental Relations, General Counsel
- Stewart L. Appelrouth, Director
How do I buy Hemispherx BioPharma stock?
Shares of Hemispherx BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Hemispherx BioPharma's stock price today?
MarketBeat Community Rating for Hemispherx BioPharma (NYSE HEB)MarketBeat's community ratings are surveys of what our community members think about Hemispherx BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Hemispherx BioPharma stock can currently be purchased for approximately $0.33.
Consensus Ratings for Hemispherx BioPharma (NYSE:HEB) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Hemispherx BioPharma (NYSE:HEB)
Analysts' Ratings History for Hemispherx BioPharma (NYSE:HEB)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Hemispherx BioPharma (NYSE:HEB)Earnings History by Quarter for Hemispherx BioPharma (NYSE HEB)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/14/2017||Q2 2017||($0.08)||$0.21 million||View||N/A|
|11/14/2016||Q3 16||($0.30)||$0.02 million||View||N/A|
|5/16/2016||Q116||($0.01)||$40.99 million||$0.04 million||View||N/A|
|5/13/2015||Q1 15||($0.02)||$0.04 million||View||N/A|
Earnings Estimates for Hemispherx BioPharma (NYSE:HEB)
Current Year EPS Consensus Estimate: $0.000 EPS
Next Year EPS Consensus Estimate: $-0.030 EPS
Dividend History for Hemispherx BioPharma (NYSE:HEB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Hemispherx BioPharma (NYSE:HEB)Insider Trades by Quarter for Hemispherx BioPharma (NYSE:HEB)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/2/2017||Adam Pascale||CFO||Buy||15,873||$0.63||$9,999.99|| |
|5/2/2017||David R Strayer||Insider||Buy||7,937||$0.63||$5,000.31|| |
|4/27/2017||Thomas K Equels||CEO||Buy||72,464||$0.69||$50,000.16|| |
|4/11/2017||Thomas K Equels||CEO||Buy||200,000||$0.50||$100,000.00|| |
|2/16/2017||Adam Pascale||CFO||Buy||6,981||$0.46||$3,211.26|| |
|2/16/2017||David R Strayer||Insider||Buy||9,892||$0.46||$4,550.32|| |
|2/16/2017||Wayne S Springate||SVP||Buy||8,014||$0.46||$3,686.44|| |
|12/22/2016||Thomas K Equels||CEO||Buy||68,493||$0.73||$49,999.89|| |
|11/1/2016||Thomas K Equels||CEO||Buy||10,000||$1.00||$10,000.00|| |
|7/8/2016||Thomas K Equels||CEO||Buy||48,000||$0.12||$5,760.00|| |
|7/1/2016||Thomas K Equels||CEO||Buy||171,000||$0.12||$20,520.00|| |
|3/18/2016||Thomas K Equels||CEO||Buy||30,000||$0.13||$3,900.00|| |
|3/11/2016||Thomas K Equels||CEO||Buy||40,000||$0.16||$6,400.00|| |
|3/10/2016||Thomas K Equels||CEO||Buy||30,000||$0.16||$4,800.00|| |
|8/20/2015||William A Carter||CEO||Buy||25,000||$0.18||$4,500.00|| |
|8/18/2015||William A Carter||CEO||Buy||25,000||$0.18||$4,500.00|| |
|8/17/2015||William A Carter||CEO||Buy||25,000||$0.18||$4,500.00|| |
|8/14/2015||Thomas K Equels||CFO||Buy||79,104||$0.18||$14,238.72|| |
|4/28/2015||William A Carter||CEO||Buy||100,000||$0.24||$24,000.00|| |
|4/27/2015||Thomas K Equels||CFO||Buy||100,000||$0.24||$24,000.00|| |
|4/21/2015||William A Carter||CEO||Buy||100,000||$0.24||$24,000.00|| |
|4/20/2015||Thomas K Equels||CFO||Buy||100,000||$0.24||$24,000.00|| |
|4/17/2015||William A Carter||CEO||Buy||73,681||$0.23||$16,946.63|| |
|4/16/2015||William A Carter||CEO||Buy||26,319||$0.23||$6,053.37|| |
|4/15/2015||Thomas K Equels||CFO||Buy||100,000||$0.23||$23,000.00|| |
Headline Trends for Hemispherx BioPharma (NYSE:HEB)
Latest Headlines for Hemispherx BioPharma (NYSE:HEB)
Loading headlines, please wait.
Hemispherx BioPharma (HEB) Chart for Sunday, October, 22, 2017